Age and sex effects on the pharmacokinetics of linezolid

Abstract.Objective: To evaluate the possible effects of age and sex on the pharmacokinetics of linezolid in healthy volunteers. Methods: A single 600-mg dose of linezolid was administered orally to young (18–40 years) and elderly (≥65 years) healthy males and females. Blood and urine samples were collected until 48 h after dosing and assayed for linezolid concentrations using a validated high-performance liquid chromatography method. Pharmacokinetic parameters were assessed using noncompartmental methods. Comparisons of the pharmacokinetic parameters for each age and sex group were performed using a two-way analysis of variance model. Pairwise comparisons were done using least-square means analysis. Results: Peak plasma drug concentrations occurred within 1.5 h after linezolid administration for males and females in both age groups. However, the maximum concentration achieved differed significantly between males and females. There was no significant difference between males and females or young and elderly for mean apparent elimination rate constant or half-life. There was no difference in mean apparent oral clearance (CLPO) between the young and elderly; however, there was a significant difference between males and females. Mean CLPO for females was ~37% less than mean CLPO for males when not corrected for body weight. Correcting for differences in weight reduced this difference to ~20%. Overall, females had a slightly lower volume of distribution than males, but this was not affected by the age of subjects. Conclusions: A dose adjustment based on age and sex is not warranted due to the wide range of linezolid concentrations that are well tolerated and the relative small difference in linezolid disposition between males and females.

[1]  P. Feldman,et al.  Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis , 1988, Antimicrobial Agents and Chemotherapy.

[2]  J. S. Daly,et al.  Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound , 1988, Antimicrobial Agents and Chemotherapy.

[3]  R. Jones,et al.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones , 1996, Antimicrobial agents and chemotherapy.

[4]  N. Hopkins,et al.  A Pharmacokinetic Evaluation of Concomitant Administration of Linezolid and Aztreonam , 1999, Journal of clinical pharmacology.

[5]  M. G. Johnson,et al.  Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[6]  J. S. Daly,et al.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. , 1988, The Journal of antimicrobial chemotherapy.

[7]  P. Feldman,et al.  The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. , 1988, Biochemical and biophysical research communications.

[8]  H. Aoki,et al.  The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria , 1998, Antimicrobial Agents and Chemotherapy.

[9]  K. Marotti,et al.  Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions , 1997, Antimicrobial agents and chemotherapy.

[10]  K. Marotti,et al.  The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin , 1997, Antimicrobial agents and chemotherapy.

[11]  J. Kilburn,et al.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents , 1996, Antimicrobial agents and chemotherapy.